Gastric carcinoma in canines and humans, a review by Hugen, S et al.
 Gastric carcinoma in canines and humans, a reviewS. Hugen a # , R.E. Thomas b,  A.J. Germanc, I.A. 
Burgenera, P.J.J. Mandigersa 
a Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht 
University, Yalelaan 108, 3584 CM Utrecht, The Netherlands 
b Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 
CL Utrecht, The Netherlands 
c School of Veterinary Science, University of Liverpool, Leahurst Campus, Chester High Road, 
Neston, Wirral CH64 7TE, UK 
 
# corresponding author 
Sanne Hugen, DVM 
Faculty of Veterinary Medicine, Utrecht University 
Yalelaan 108 
3584 CM  
Utrecht, The Netherlands 
Tel: 0031-(0)30-2533943 
e-mail address: s.hugen@uu.nl 
 
Abstract: 
Gastric carcinoma (GC) is the most common neoplasm in the stomach of dogs. Although incidence in 
the general population is reported to be low, breed-specific GC has a high incidence. Median age at 
presentation ranges from 8 to approximately 10 years. The disease is mostly located in the lesser 
curvature and antropyloric region of the stomach. Unfortunately, diagnosis is usually made when the 
disease is at an advanced stage and, therefore, prognosis is poor. Due to similarities in clinical 
presentation, diagnosis, histology and prognosis, canine GC may serve as a valuable model for human 
GC.  Extensive pedigrees of canine gastric carcinoma cases could reveal insights for human gastric 
carcinoma.  Putative species differences include the role of Helicobacter in pathogenesis, the wide array 
of genetic data and screening available for humans, and treatment protocols that are available for human 
GC.Introduction:  
The overall prevalence of gastric carcinoma (GC) in dogs is low although, in a small number of 
breeds, a higher incidence has been reported 1. The familial occurence of canine GC, combined with 
the narrow genetic basis of our current purebred populations offers opportunities to investigate the 
genetic background of (familial) human gastric carcinoma. Potentials advantages for such comparative 
research includes the fact that dogs share the same environment as humans, the fact that within 
pedigrees genetic variance is reduced compared to man, and the fact that lifespan is relatively shorter 
2. This paper gives an overview of the current knowledge of the clinical and genetic characteristics of 
GC in dogs and humans. It will address the complete scope of aetiology, clinical presentation, 
diagnosis, therapy and prognosis and genetics of canine and human gastric carcinoma, but will not be 
an in-depth review of human gastric carcinoma. 
 
Aetiology  
Human gastric carcinoma ranks as the fifth most prevalent cancer worldwide, and is the third cause of 
cancer-related death in men and fifth in women3. Cancer of the gastro-oesophageal junction (GEJ) is 
considered a separate group with different epidemiology and aetiology and is outside the scope of this 
review 4, 5. The aetiology of human gastric carcinoma is complex and incompletely understood. Besides 
hereditary cancer syndromes, known risk factors include smoking, alcohol consumption, high salt and 
fat consumption, obesity, low fruit and vegetable consumption, ageing, low economic status, other 
gastric diseases, and Helicobacter pylori infection 6, 7. H. pylori infection is the best studied of these and 
causes a three-to-six fold increase in gastric cancer risk. About 1 - 3 % of people infected with H. pylori 
develop gastric cancer. It causes chronic active inflammation, mucosal damage and altered gene 
expression and epigenetic changes in multiple genes, eventually leading to carcinogenesis 8-11.  
The intestinal type (IGC) and diffuse type  (DGC) of gastric carcinoma are believed to result from 
distinct pathogenetic pathways. The IGC form develops after stepwise progression from chronic gastritis 
to atrophic gastritis, metaplasia, dysplasia to intestinal type carcinoma.Diffuse gastric carcinoma 
however is thought to arise de novo by downregulation of CDH17, 12. Early stages of DGC are 
characterised by, often multiple, foci of superficial signet ring carcinoma in situ 12-14. Multiple hereditary 
cancer syndromes increase risk of gastric carcinoma. Hereditary diffuse gastric cancer (HDGC) carries 
a cumulative lifetime risk of up to 70% in men and 56 % in women of developing gastric carcinoma for 
mutation carriers 15, 16.  H. pylori infection does not appear to be associated with HDGC 17. Other, rare, 
hereditary cancer syndromes increasing the risk of gastric carcinoma are: Lynch syndrome, gastric 
adenocarcinoma and proximal polyposis of the stomach (GAPPS), familial adenomatous polyposis, Li-
Fraumeni syndrome and Peutz-Jeghers syndrome 18-20.  
 
Similar to human GC, the aetiology of canine gastric carcinoma is complex and poorly understood, but 
it is believed that both environmental and genetic factors play a role 1, 21. Long-term administration of 
N-Nitrosamines can lead to induction of gastric carcinoma, although the relevance of this in clinical 
settings in unclear 22. The strong breed predisposition and familial occurrence described for several 
canine breeds, including the Belgian Shepherd dog, indicates the importance of genetic factors in the 
aetiology of gastric cancer 1, 21, 23. In addition, some very small subgroups of canine gastric cancer may 
have different aetiologies. For example few cases of hypertrophic gastritis (Ménétriers-like disease) 
progressing into superficial signet-ring-type gastric carcinoma are reported 24, 25. In the Norwegian 
Lundehunde, atrophic gastritis, characterised by reduction in parietal cells and hyperplasia of 
neuroendocrine cells, is reported to be associated with gastric tumour development. In these dogs, 
hypergastrinaemia secondary to atrophy may be important in carcinogenesis 26, 27. Unlike in humans, 
precursor lesions are not frequently described in dogs that develop gastric carcinoma and no convincing 
relationship could be demonstrated between gastric polyps that are sporadically identified, Helicobacter, 
and gastric carcinoma 28. H. pylori is infrequently found in the stomach of dogs, likely due to the 
different glycosylation profile and the ability of different strains to adhere to specific host glycan 
receptors 29. However, different ‘Non-Helicobacter-pylori-type Helicobacter species (NHPH) are 
frequently encountered in the stomach of both healthy dogs and those showing signs of gastrointestinal 
disease 30, 31. The pathogenic significance of these Helicobacter species remains controversial in dogs, 
since a clear relationship between NHPH and gastritis has not been established 32. Therefore, a possible 
role in the aetiology of gastric carcinoma is questionable. 
 
Clinical presentation of gastric carcinoma  
Humans 
Incidence of gastric carcinoma is particularly high in Eastern Asia with Central and Eastern Europe and 
South America second and third. Stomach cancer rates are approximately twice as high in males as in 
females 33. The vast majority of gastric carcinomas arise sporadically. Familial clustering is apparent in 
less than 15% of cases and most of these are not associated with a definitive germline mutation 34, and 
hereditary cancer syndromes are associated with less than 3% of gastric cancer cases 35, 36. It is only in 
cases with mutations in germ cells, that the risk of GC is constitutionally passed on to the progeny. 
The epidemiology and predominant location of gastric carcinoma varies geographically due to a 
complex of genetic and environmental factors 7, 37. Carcinomas in the body or the corpus of the stomach 
are typically located along the greater or lesser curvature 38. Similarly, the location of the tumour in 
hereditary forms of gastric carcinoma also appears to vary with racial and geographical differences 17. 
Gastric carcinoma patients are typically middle-aged to older with most patients aged between 50 and 
70 years at presentation. Patients younger than 30 years of age are rarely seen 39. 
Clinical signs of gastric carcinoma in humans tend to emerge late in the development of the disease. 
Therefore, the cancer is often at an advanced stage at presentation 40 and more than half the patients 
have lymph node metastasis at first clinical presentation or surgery 41. 
 
Dogs 
According to a recent Norwegian survey, canine GC accounts for only 0.16% of all reported canine 
cancer cases 1. This is in accordance with earlier reports in which GC cases accounted for less than 1% 
of all canine tumours 42, 43. However, GC is the most common neoplasm in the stomach of dogs compared 
to the less frequently seen leiomyo(sarco)ma, gastro-intestinal stromal tumours (GIST) and lymphoma 
44-48. An increased prevalence of gastric carcinoma is present in several dog breeds with breed 
predispositions reported for the Staffordshire bull terrier, Rough Collie 49, Bouvier des Flandres, 
Standard poodle, Norwegian elkhound 1, Hovawart and Chow-Chow 45, 47 and, most convincingly, in the 
Belgian shepherd, Tervueren and Groenendael 1, 21, 23, 50.  
Gastric carcinoma is typically a disease of middle aged to older dogs. Median age at presentation ranges 
from 8 to approximately 10 years 45, 49, 51-54, although there are anecdotal reports of cases less than 5 
years of age 52.  Comparable to humans, GC seems to occur more frequently in male than female dogs. 
Seim-Wikse et al. reported a statistically different odds ratio (OR) for males versus females of 2.3, with 
only a male to female ratio of 1.2:1 1. However, there are other ratios reported varying from 1.4:1 to 
2.75:1 21, 45, 47, 53. This variation might be explained by the use of relatively small numbers of dogs in 
these studies as well as phenotypical diversity. There are indications that the male: female ratio is 
different in different subtypes of gastric adenocarcinoma 43.  
As in humans, clinical signs of gastric cancer in dogs are usually mild to absent during the early stages 
of the disease. The most common clinical signs are vomiting (40-95% of cases), anorexia (48-52%) 
weight loss (23-52%), and lethargy (25-28%) 45, 47, 54. Gualtieri et al found no strong relationship between 
the extent of gastric wall involvement of the tumour and the severity of vomiting. Haematological and 
biochemical changes are typically absent or small and may consist of mild anaemia, increased liver 
enzymes, hypoglycaemia, hyperproteinaemia, hypalbuminaemia and prolonged clotting times 45, 47. 
Metastasis has classically been reported to occur at a high rate, and has typically reached 70-90% by the 
time of diagnosis 43, 45, 49, 54. A possible explanation for this could be that the early stage of the disease is 
often missed due to the mild nature of the clinical signs meaning that veterinary advice is not sought. 
The most common site of metastasis is the regional lymph nodes. More distant sites frequently reported 
are the liver, lung, duodenum, adrenal glands, pancreas, omentum and spleen. In a few more recent 
smaller studies metastasis percentage at presentation was lower 47, 55-57.  It is unclear if this is due to 
lesser malignancy in these cases, earlier presentation or the diagnostic protocol used. 
The primary tumour in canine gastric carcinoma is most often located in the lesser curvature and pyloric 
region of the stomach but can extend throughout the stomach 21, 43, 45, 54, 57. The gastric wall is often 
markedly thickened and contains abundant fibrous tissue. This scirrhous aspect of the tumour can make 
the stomach wall non-distensible, a condition sometimes referred to as linitis plastica. Ulceration of the 
mucosal surface is present in about half of the cases and may be characterized by a necrotic centre with 
a raised rim 43, 45, 49.  
 
Diagnosis 
In humans, different diagnostic guidelines vary with the geographic location. However, when gastric 
carcinoma is suspected, endoscopy with multiple biopsies is recommended consistently in all national 
and international guidelines 58, 59. Over 90% of tumour cases are diagnosed by endoscopy 60, partially in 
conjunction with methods to improve visualization of the mucosa in endoscopy such as confocal 
endomicroscopy or narrow band imaging, to detect vascular patterns, to improve sensitivity and 
specificity 61, 62. There is broad consensus that staging is mandatory for decision making: This can be 
performed by physical examination, clinicopathological testing (e.g. complete blood count, tests of liver 
and kidney function), and advanced imaging such as abdominal/pelvic CT (possibly combined with 
PET-CT) and either CT or radiography of the thorax. However, throughout Europe, endoscopic 
ultrasonography is the method of choice for the detection of locoregional metastasis and to assess tumour 
infiltration depth. Laparoscopy, with or without peritoneal wash to detect malignant cells cytologically, 
is recommended to exclude occult metastasis in surgical candidates 59, 63, 64.  
 
In dogs, the clinical signs, signalment and family history are often sufficient to include GC as a 
differential diagnosis. Furthermore, in breeds with a strong breed predisposition and a large database of 
confirmed cases, family history may contribute to the suspicion of gastric carcinoma. Abdominal 
radiographs may show thickening of the gastric wall, loss of (cranial) abdominal detail, cranial 
abdominal mass effect, or no specific findings 45, 47. However, this type of diagnostic investigation is 
now less commonly performed because of the advent of ultrasonography and CT. 
Abdominal ultrasonography enables the morphological assessment of the stomach wall, abdominal 
lymph nodes, and other possible metastatic sites.  This may enable a tentative diagnosis of gastric 
carcinoma to be made and can direct further diagnostic work-up. The majority of gastric carcinomas are 
ultrasonographically sessile masses involving all layers of the stomach, and may extend through the 
serosal surface. Evidence of ulceration and lymphadenopathy may also be apparent, but ultrasonography 
has relatively poor sensitivity for detection of such lesions. Further, dogs with gastric carcinoma share 
many ultrasonographic features with dogs that have gastric lymphoma 46, 65. Although ultrasonography 
is a valid tool in the diagnostic approach of gastric carcinoma,  recent studies found only 50-58% 
compatibility of ultrasonography in clinical cases of stomach cancer 47, 66.  
CT scans are very helpful in assessing stomach wall, lymph nodes, and other indications of metastasis 
47, 56, but challenges in interpreting the morphology of the stomach wall persist, most commonly due to 
gas artefacts or incomplete distension. This can be overcome by using Helical Hydro CT, which offers 
enhanced contrast and stomach extension; indeed, in a recent feasibility study, imaging results 
corresponded well with histology of gastric and lymph node biopsies 57.  
Endoscopy is the diagnostic method of choice for GC 44, 45, 67, since the epithelial origin of the lesions 
typically makes for a high rate of diagnostic accuracy 50.  However, in some cases it can be difficult to 
differentiate changes associated with gastric carcinoma from inflammation 68. Diagnostic methods to 
improve the evaluation of gastric mucosa in endoscopy are not routinely used, but may be available in 
the future to aid in vivo diagnosis of (early) gastrointestinal disease 69. 
Exploratory coeliotomy is the gold standard for diagnosing GC, but is highly invasive. Its main benefits 
are the fact that it enables full thickness gastric biopsies to be acquired, and also a complete evaluation 
of abdominal metastasis. A further advantage of coeliotomy is the potential that simultaneous surgical 
removal can also be considered if indicated. 
 
Histology 
Ninety percent of human gastric cancers are adenocarcinomas, and these are subdivided by histological 
appearance using a scheme referred to as the Laurén classification into diffuse and intestinal types 70 or 
classified according to the WHO-guidelines according to the most dominant histological pattern. The 
WHO classification recognises 4 main types: (i) Tubular adenocarcinomas with prominent dilated or 
slit-like and branching tubules. Tumour	 cell	 morphology	 is	 columnar,	 cuboidal,	 or	 flattened	 by	
intraluminal	 mucin; (ii) papillary adenocarcinomas, well-differentiated exophytic tumours with 
elongated processes lined by cylindrical or cuboidal cells and a fibrovascular connective tissue core; 
(iii) mucinous adenocarcinomas in which extracellular mucin pools constitute over 50% of the tumour	
The	tumour	cells	can	form	glands	of	columnar	mucous-secreting	epithelium	or	irregular	cell	clusters.	
Occasional	scattered	signet	ring	cells	may	be	present	but	do	not	dominate	; and,  (iv) signet-ring cell 
carcinomas where > 50% of the tumour consists of malignant cells containing intracytoplasmic mucin 
and the nuclei may be displaced against cell membranes 38. Histological subtyping is important because 
of differences in likely pathogenesis, diagnostic testing, therapy and prognosis 14, 59, 71-73. The term ‘early 
gastric cancer’ (ECG) is used for a carcinoma limited to the mucosa or the mucosa and submucosa. In 
addition, ‘precursor lesions’ may be recognised in asymptomatic patients and in tissue surrounding 
cancerous lesions Chronic atrophic gastritis and intestinal metaplasia and dysplasia commonly precede 
and/or accompany gastric carcinoma of the intestinal type, although only a small portion of these patients 
progress to develop gastric cancer 38, 74. 
 
In dogs, surgical or endoscopic biopsies are mostly assessed according to a scheme adapted from the 
human WHO classification with six major types based on predominant histological growth pattern: 
Papillary, tubular, tubulopapillary, mucinous, signet ring or undifferentiated. The other classification 
system commonly used is the ‘Laurén’ classification with the intestinal type tumours forming poorly- 
to well-differentiated glands and the diffuse type of GC being composed of poorly cohesive cells and 
lacking glandular structures. The diffuse type tumour will often contain cells with large amounts of 
intracytoplasmic mucin called signet ring cells 70, 75. Classification according to the Laurén scheme, with 
less subgroups gives more power to often small case sets and allows for easier translation to human 
medicine. The clinical and prognostic significance of the subtypes, irrespective of Laurén or WHO-
classification systems, in canine GC has not been clearly demonstrated so far 53.  
 
 
Biomarkers 
In human medicine, the search for prognostic or predictive biomarkers for gastric carcinoma is important 
in the field of personalised medicine. Indeed, a number of candidate biomarkers have been discovered. 
HER-2 is a proto-oncogene encoded by the ERBB2 gene, and is a tyrosine kinase receptor belonging to 
the epidermal growth factor receptor (EGFR) family 76. It is an important predictive biomarker for 
gastric carcinoma 77. HER-2 testing is recommended in both American, European and Asian gastric 
cancer guidelines in patients with metastatic or recurrent gastric cancer under consideration for palliative 
chemotherapy. When score of immunohistochemical staining for HER-2 is 3+, targeted therapy is 
indicated 58, 64, 78-80.  The c-Met proto-oncogene encodes the c-Met receptor. High MET gene 
amplification and expression in gastric cancer serve as an independent negative prognostic factor. C-
Met has also been identified as a possible therapeutic target. A third potential biomarker with possible 
predictive value is the ligand of PD-1, an immune-inhibitory receptor of the CD28 family which plays 
a role in tumour immune escape 77. 
 
The tyrosine kinases HER-2 and EGFR (Her-1) have recently been investigated in canine gastric 
adenoma and carcinoma. HER-2 positivity (3+ staining) was present in 11 of 19 gastric tumours, 
independent of histological subtype or malignancy. EGFR expression was present in 42% of samples 
and significantly more in intestinal-type than diffuse-type tumours 81. The potential implication of these 
proteins as predictive or prognostic biomarkers needs further investigation and confirmation with gene 
expression studies82. 
Recently, serum gastrin expression was investigated as a possible biomarker in dogs with gastric 
carcinoma. This was prompted by a case report of high gastrin in a cattledog with hypergastrinaemia 
and mucinous gastric carcinoma, and the confirmed association between atrophic gastritis and gastric 
neoplasia in Norwegian Lundehunde 27. However, serum gastrin was not useful as a single biomarker 
52. In the search for a biomarker to aid diagnosis of GC in dogs, HER-3 expression and CDX-2 
expression have also been investigated. The transmembrane glycoprotein HER-3 is overexpressed in 
various human cancers including stomach cancer 83, 84. The nuclear transcription factor CDX-2 is a 
reliable immunohistochemical marker for human gastrointestinal adenocarcinoma and metastases 85, 86. 
Marked HER-3 expression and CDX-2 expression was demonstrated in the canine gastric 
adenocarcinomas and the lymph node metastasis, and both HER-3 expression and CDX-2 expression 
was not detected in normal canine gastrointestinal tissues 55. Thus, complementing standard 
histological examination of tissue samples with immunohistochemistry may improve diagnostic 
accuracy and better identify metastasis 55, 56.   
Therapy and prognosis 
In humans, treatment of gastric cancer is highly dependent on clinical staging and varies in invasiveness 
according to national and international guidelines. Early gastric cancer lesions can be treated by 
endoscopic resection and have a favourable prognosis. Indeed, national screening programmes in Japan 
and Korea have identified many more patients with early gastric cancer in these countries 58, 87. Screening 
may encompass double contrast radiography studies followed by upper endoscopy, or only upper 
endoscopy 88.  
For all patients with advanced gastric cancer without distant metastasis, curative surgery is the aim. 
Margins of > 5 cm for diffuse gastric cancer and 2-3 cm for intestinal type cancer should be maintained 
and depending on the grade of cancer D1 lymph nodes (perigastric nodes directly attached along the 
lesser curvature and greater curvatures of the stomach) or D2 lymph node (D1 plus nodes along the left 
gastric artery, common hepatic artery, celiac trunk, splenic hilus, and splenic artery) resection is 
performed 89, 90.   
In people carrying a mutation for HDGC, prophylactic total gastrectomy is offered in early adulthood, 
typically at an age 5 years younger than the youngest affected family member 73, 91. 
Peri-operative chemotherapy has been widely adopted as standard care throughout the world. Although 
in north America chemoradiotherapy is often the first choice, where 5-FU and Leucovorin are combined 
with radiotherapy78. Much used protocols include ECF (epirubicin, cisplatin and 5-FU) or ECX 
(epirubicin, cisplatin and capecitabine) in Europe and the UK 64, 92 and S-1 sometimes with addition of 
cisplatin or capecitabine plus oxaliplatin in Asia58, 93. For non-resectable disease, palliative 
chemotherapy is used, with the addition of trastuzumab in HER2 positive patients 64, 78, 80. 
 
The only potentially curative treatment option for gastric carcinoma in the dog is surgical resection.  
Malignancies should be resected with wide margins of 1-2 cm of apparently normal tissue around the 
tumour. Unfortunately, in many cases, the extent and location (especially when the lesser curvature is 
involved) precludes such dissection. Tumours in the antropyloric region may be resected by partial 
gastrectomy and gastroduodenostomy 45. Pylorectomy with gastroduodenostomy has a poor long-term 
survival time in dogs with malignant neoplasia. Median overall survival time of dogs with malignant 
neoplasia and metastasis was only 33 days (95% CI 14-578) 68. Surgical resection in 10 cases of gastric 
adenocarcinoma resulted in a median survival time of 72 days (range 3 months to 4 years) 45. Survival 
after surgical resection alone in 8 dogs resulted in a short survival of between 2 days and 10 months 54. 
Chemotherapy alone or adjuvant chemotherapy after surgical resection has been described in small case 
studies and case reports only and may be of limited additional value in advanced disease. Chemotherapy 
protocols used include carboplatin, doxorubicin, doxorubicin combined with cyclophosphamide and 5-
fluorouracil, followed by cisplatin and 5-fluorouracil in combination with cyclophosphamide 47, 54, 56, 94.  
In a report of three cases, survival time was 9 weeks, 9 weeks and 7.5 months, respectively 54. In other 
reports of a single case, survival time after surgery and adjuvant chemotherapy was 81 days and in 114 
days, respectively 47, 94.  
Total gastrectomy has been performed sporadically in dogs with gastric carcinoma, but ethical questions 
remain in performing this extensive surgery in dogs with such advanced disease, because of post-
operative quality of life and expected prognosis with metastatic disease 45, 95. 
Surgery with adjuvant chemotherapy of gastric adenocarcinoma confined to the mucosa or submucosa 
may have a more favourable prognosis 56. Poor prognosis of dogs with gastric carcinoma is likely 
influenced by late presentation. Recent evaluation of more than 80 biopsies at the Department of 
Pathobiology, Faculty of Veterinary Medicine, Utrecht University, has shown that it is not always 
possible to determine the extent of neoplastic infiltration into the muscular layers based on the scant 
tissue collected during endoscopic biopsy (unpublished observations). This additional uncertainty 
further complicates the decision as to whether or not surgery is indicated. Furthermore, the less well 
organised diffuse-type or signet ring- type tumours are considered to have a less favourable prognosis 
then the more glandular tumours. There are indications that these tumours might metastasise earlier 96. 
To the authors knowledge there are currently no screening programs in dogs. 
 
Genetics  
Humans 
In humans, most cases of gastric cancer are sporadic without evidence of germline mutations, and arise 
as a result of the complex interplay between environmental risk factors and (acquired) genetic factors. 
These genetic factors may be the result of somatic gene mutations, single nucleotide polymorphisms 
(SNPs) in known candidate genes, chromosomal and microsatellite instability, or changes in miRNA 
profile or epigenetic landscape. Through numerous studies, a multitude of genes and genomic regions 
have been implicated in gastric cancer and disease progression. For example, APC, TP53, NME1 have 
been implicated with loss of heterozygosity 97. Microsatellite instability is found in up to 38% of sporadic 
gastric cancer cases and high microsatellite instability is associated with better prognosis 98, 99. SNPs in 
inflammatory genes have also been extensively studied, particularly in genes involved in the host 
response to H. pylori infection 100, 101. A positive association between IL1 markers and increased risk of 
gastric cancer have also been confirmed by several meta-analyses 102, 103. However, ethnical and 
geographical factors, histological subtype (diffuse vs intestinal), and anatomical location of the tumour 
are also of importance in this association 35, 104. Another gene with an established gene polymorphism 
increasing gastric cancer risk is IL17A 105, 106. The host response to H. pylori infection and its’ influence 
on gastric cancer development is also reflected in the MUC1  polymorphism, with the G allele conveying 
an almost 30% reduced risk of gastric cancer 107. 
The PSCA gene, encoding prostate stem cell antigen identified with a Genome Wide Association Study 
(GWAS) was shown in multiple patient cohorts to hold a polymorphic genetic variation increasing the 
risk of gastric cancer development. PSCA was revealed to have a role in the inhibition of epithelial cell 
proliferation 108, 109. A high level of evidence for association with risk of developing sporadic gastric 
carcinoma was confirmed for polymorphisms of PSCA and MUC1, in addition to MTX1, PRKAA1, 
PLCE1, TGFBR1, PKLR, GSTP1, CASP8 and TNF 110. In addition to these and other risk-conferring 
genetic factors, a large number of nonsynonymous somatic mutations are present in gastric 
adenocarcinomas. Frequently mutated genes include TP53, genes of cell adhesion pathways, chromatin 
remodelling genes and, in diffuse type carcinomas specifically, RHOA – a RAS homology family 
member 111, 112. 
 
Hereditary diffuse gastric cancer is an autosomal dominant condition caused by a germline mutation in 
the CDH1 gene. HDGC is a clinical diagnosis based on the criteria of the International Gastric Cancer 
Linkage Consortium, characterized by early-onset, multigenerational DGC and lobular breast cancer17. 
The CHD1 gene encodesE-cadherin an important cell adhesion molecule. The mutation is most 
frequently heterozygous and can take many forms and involve both coding and non-coding regions16. 
Loss of function of the remaining allele can be caused by genetic and epigenetic changes such as 
promoter hypermethylation and loss of heterozygosity 113. CHD1 mutations explain about 10-40% of 
hereditary diffuse gastric cancer cases 17, 91, 114. 
A truncating allele in the related protein alpha-E Catenin was identified in a Dutch family with HDGC 
without CDH1 mutation through exome sequencing 115. Alpha-E-catenin acts together with β-catenin in 
connecting the cytoplasmic domain of E-cadherin to the cytoskeleton.  Mutations in the catenin gene 
family however did not appear to be of more widespread importance in CDH1-negative HDGC 
families116.  
Recently, novel germline mutations in non-CHD1 hereditary gastric cancer have been identified.  
Multiple genetic mutations in the mitogen-activated protein kinase kinase kinase (MAP3K6) were 
described in patients with familial gastric cancer from different families 117. And candidate mutations in 
BRCA1, STK11, SDHB, PRSS1, ATM, MSR1 and PALB2 were identified in individual CDH1 
negative HDGC family members 16. However, in the majority of families with hereditary gastric cancer, 
the underlying genetic cause remains unknown. 
 
Dogs 
Depending on the patient population at a given research institute, most cases of canine gastric carcinoma 
are likely to be spontaneous or familial. For instance in the Netherlands, sporadic cases are rare, and the 
majority of cases occur in interrelated dogs (unpublished observation). Sporadic cases of GC arise 
through acquired somatic mutations during life, possibly in conjunction with environmental risk factors 
and epigenetic events. These mutations likely include cell cycle proteins 53. KRAS exon 2 status has been 
evaluated in canine gastric adenomas and adenocarcinomas in one recent study. The KRAS gene encodes 
a small protein involved in signal transduction between transmembrane receptors (like the EGF-receptor 
superfamily) and the nucleus 118 and was mutated in one of 14 canine gastric carcinoma cases 81. 
In familial canine gastric carcinoma, germline mutations are thought to be passed on through generations 
with environmental and epigenetic factors contributing to disease expression. However, to date no 
known mutations in dogs with GC have been published. 
 
Conclusion  
Similar to human GC, canine GC is a heterogeneous disease with limited treatment options and a poor 
prognosis. Whilst it is appreciated that genetic and environmental factors play an important role in cases 
of gastric carcinoma, much remains unknown about the aetiology. Given the frequent occurrence of 
familial, presumed hereditary, cases of canine gastric carcinoma in some regions, an opportunity exists 
for research into the genetics of gastric carcinoma. Extensive pedigrees of canine gastric carcinoma 
cases may provide a valuable model for human hereditary gastric carcinoma. And due to the unique 
characteristics of inbred dog populations a far smaller number of animals and DNA markers is needed 
119. For a better prognosis of canine GC in the future and to take advantage of the vast amount of research 
conducted in humans, it is important to identify cases as early as possible in the course of the disease. 
A possible benefit for cost-effective screening patients with increased risk of canine familial gastric 
cancer remains to be investigated. 
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